Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2014-04-17 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
董事会审计委员会2013年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Board Audit Committee of a company regarding its activities and oversight for the fiscal year 2013. It discusses the committee's meetings, supervision of external auditors, review of financial reports, evaluation of internal controls, and coordination with auditors. It is not the full annual report or audit report itself but a specific committee report on audit committee duties and performance. The document length is 2206 characters, which is relatively short but contains substantive content about audit committee activities rather than just an announcement. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and related committee reports on audit activities, excluding full annual reports. Therefore, the appropriate classification is AR with high confidence. FY 2013
2014-04-17 Chinese
第七届董事会第四十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 中源协和干细胞生物工程股份公司 dated April 18, 2014. It details the approval of the 2013 annual report, 2013 board work report, 2013 financial statements, profit distribution plan, and the 2014 first quarter report. It also mentions the appointment of the audit firm for 2014 and references the audit fees. The document is a formal announcement of board decisions rather than the full reports themselves. The length is short (1678 characters), and it primarily records resolutions passed by the board, including approval of reports and plans to submit them to the shareholders' meeting. This fits the category of Board/Management Information (MANG), which covers announcements of board decisions and management changes or approvals. It is not the full annual report (10-K), interim report (IR), or audit report (AR) itself, nor is it a simple announcement of report publication (RPA). Therefore, the best classification is MANG with high confidence.
2014-04-17 Chinese
2013年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as the "2013年度独立董事述职报告" which translates to "2013 Annual Independent Directors' Report." It details the independent directors' duties, attendance, opinions on company matters such as related party transactions, external guarantees, appointment of senior management, profit distribution, auditor appointment, and information disclosure compliance for the year 2013. The content is a detailed report on the independent directors' activities and oversight during the year, which is a form of management or board report rather than a full annual report or audit report. It is not a simple announcement or certification but a substantive report on governance and management oversight. Therefore, the document fits best under Board/Management Information (MANG) as it relates to board activities and management oversight.
2014-04-17 Chinese
2013年年度报告
Annual Report Classification · 100% confidence The document is titled "中源协和干细胞生物工程股份公司 2013 年年度报告" which translates to "Zhongyuan Union Stem Cell Bioengineering Co., Ltd. 2013 Annual Report." It contains detailed financial data, management discussion and analysis, board reports, accounting data, and other comprehensive information typical of a full annual report. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes audited financial statements, auditor's opinion, detailed business and financial analysis, risk disclosures, and corporate governance information. These characteristics align with the definition of an Annual Report (10-K). There is no indication that this is merely an announcement or a certification, so it is not classified as RPA or RNS. Therefore, the document is classified as an Annual Report (10-K). FY 2013
2014-04-17 Chinese
2013年年度报告摘要
Annual Report Classification · 100% confidence The document is titled "中源协和干细胞生物工程股份公司 2013 年年度报告摘要" which translates to "Zhongyuan Xiehe Stem Cell Bioengineering Co., Ltd. 2013 Annual Report Summary." It contains detailed financial data for the year 2013, including total assets, net profit, cash flow, shareholder information, management discussion and analysis, business segments, R&D expenditures, and cash flow analysis. The document is comprehensive and includes substantive financial data and analysis for the full fiscal year 2013. It is not a brief announcement or a certification but a full annual report summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2013
2014-04-17 Chinese
2014年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2014 年第一季度报告" which translates to "2014 First Quarter Report." It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2014. The document includes actual financial figures, analysis of changes in financial items, shareholder information, and management assurances about the accuracy of the report. The length of the document is substantial (15,000 characters), and it is not merely an announcement or a certification. The content fits the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data and analysis. Therefore, the appropriate classification is IR. Q1 2014
2014-04-17 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.